Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 2
1977 3
1978 1
1979 4
1980 3
1981 6
1982 6
1983 12
1984 15
1985 24
1986 10
1987 17
1988 23
1989 19
1990 23
1991 32
1992 28
1993 37
1994 32
1995 38
1996 49
1997 45
1998 57
1999 58
2000 65
2001 62
2002 65
2003 92
2004 82
2005 98
2006 111
2007 88
2008 100
2009 114
2010 120
2011 143
2012 184
2013 163
2014 207
2015 196
2016 210
2017 233
2018 224
2019 249
2020 240
2021 216
2022 195
2023 185
2024 52

Text availability

Article attribute

Article type

Publication date

Search Results

3,750 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Increased risk for embryonal tumors"
Page 1
Melanoma Risk Factors and Prevention.
Dzwierzynski WW. Dzwierzynski WW. Clin Plast Surg. 2021 Oct;48(4):543-550. doi: 10.1016/j.cps.2021.05.001. Epub 2021 Jul 2. Clin Plast Surg. 2021. PMID: 34503715 Review.
In the Western population, 1 out of every 50 individuals will develop melanoma. The incidence of melanoma is increasing faster than any other malignancy. The development of melanoma is multifactorial arising from an interaction between genetic susceptibility and environmen …
In the Western population, 1 out of every 50 individuals will develop melanoma. The incidence of melanoma is increasing faster than a …
Melanoma.
Schadendorf D, van Akkooi ACJ, Berking C, Griewank KG, Gutzmer R, Hauschild A, Stang A, Roesch A, Ugurel S. Schadendorf D, et al. Lancet. 2018 Sep 15;392(10151):971-984. doi: 10.1016/S0140-6736(18)31559-9. Lancet. 2018. PMID: 30238891 Review.
For more than 40 years, few treatment options were available, and clinical trials during that time were all unsuccessful. Over the past 10 years, increased biological understanding and access to innovative therapeutic substances have transformed advanced melanoma in …
For more than 40 years, few treatment options were available, and clinical trials during that time were all unsuccessful. Over the pa …
Molecular targeted therapy of glioblastoma.
Le Rhun E, Preusser M, Roth P, Reardon DA, van den Bent M, Wen P, Reifenberger G, Weller M. Le Rhun E, et al. Cancer Treat Rev. 2019 Nov;80:101896. doi: 10.1016/j.ctrv.2019.101896. Epub 2019 Sep 11. Cancer Treat Rev. 2019. PMID: 31541850 Free article. Review.
More than 90% of glioblastomas are isocitrate dehydrogenase (IDH)-wildtype tumors. Incidence increases with age, males are more often affected. ...Improved clinical trial designs using pharmacodynamic endpoints in enriched patient populations will be r …
More than 90% of glioblastomas are isocitrate dehydrogenase (IDH)-wildtype tumors. Incidence increases with age, males are mor …
Advances in Risk Classification and Treatment Strategies for Neuroblastoma.
Pinto NR, Applebaum MA, Volchenboum SL, Matthay KK, London WB, Ambros PF, Nakagawara A, Berthold F, Schleiermacher G, Park JR, Valteau-Couanet D, Pearson AD, Cohn SL. Pinto NR, et al. J Clin Oncol. 2015 Sep 20;33(27):3008-17. doi: 10.1200/JCO.2014.59.4648. Epub 2015 Aug 24. J Clin Oncol. 2015. PMID: 26304901 Free PMC article. Review.
Risk-based treatment approaches for neuroblastoma have been ongoing for decades. However, the criteria used to define risk in various institutional and cooperative groups were disparate, limiting the ability to compare clinical trial results. ...
Risk-based treatment approaches for neuroblastoma have been ongoing for decades. However, the criteria used to define risk in …
Molecular stratifications, biomarker candidates and new therapeutic options in current medulloblastoma treatment approaches.
Menyhárt O, Győrffy B. Menyhárt O, et al. Cancer Metastasis Rev. 2020 Mar;39(1):211-233. doi: 10.1007/s10555-020-09854-1. Cancer Metastasis Rev. 2020. PMID: 31970590 Free PMC article. Review.
Multimodal treatment consisting of surgery, radiation therapy, and chemotherapy reduced cumulative incidence of late mortality but increased the incidence of subsequent neoplasms and severe, incapacitating chronic health conditions. ...These have distinct origin, de …
Multimodal treatment consisting of surgery, radiation therapy, and chemotherapy reduced cumulative incidence of late mortality but increa …
Relationship between genetically determined telomere length and glioma risk.
Saunders CN, Kinnersley B, Culliford R, Cornish AJ, Law PJ, Houlston RS. Saunders CN, et al. Neuro Oncol. 2022 Feb 1;24(2):171-181. doi: 10.1093/neuonc/noab208. Neuro Oncol. 2022. PMID: 34477880 Free PMC article.
BACKGROUND: Telomere maintenance is increasingly recognized as being fundamental to glioma oncogenesis with longer leukocyte telomere length (LTL) reported to increase risk of glioma. To gain further insight into the relationship between telomere genetics and ris …
BACKGROUND: Telomere maintenance is increasingly recognized as being fundamental to glioma oncogenesis with longer leukocyte telomere length …
Low-grade Gliomas.
Schiff D. Schiff D. Continuum (Minneap Minn). 2017 Dec;23(6, Neuro-oncology):1564-1579. doi: 10.1212/CON.0000000000000537. Continuum (Minneap Minn). 2017. PMID: 29200111 Review.
Moreover, the rarity of these tumors makes clinical trials to ascertain optimal care challenging. ...Preliminary results from a large randomized trial suggest chemotherapy is of comparable effectiveness to radiation therapy for one molecular subtype of …
Moreover, the rarity of these tumors makes clinical trials to ascertain optimal care challenging. ...Preliminary results from …
Neoadjuvant treatment for stage III and IV cutaneous melanoma.
Gorry C, McCullagh L, O'Donnell H, Barrett S, Schmitz S, Barry M, Curtin K, Beausang E, Barry R, Coyne I. Gorry C, et al. Cochrane Database Syst Rev. 2023 Jan 17;1(1):CD012974. doi: 10.1002/14651858.CD012974.pub2. Cochrane Database Syst Rev. 2023. PMID: 36648215 Free PMC article. Review.
Neoadjuvant treatment may increase the rate of AEs, but the evidence is very uncertain (26% versus 16%, risk ratio (RR) 1.58, 95% CI 0.97 to 2.55; 2 studies, 162 participants; very low-certainty evidence). We are very uncertain if neoadjuvant treatment increases …
Neoadjuvant treatment may increase the rate of AEs, but the evidence is very uncertain (26% versus 16%, risk ratio (RR) 1.58, …
Neuroblastoma.
Davidoff AM. Davidoff AM. Semin Pediatr Surg. 2012 Feb;21(1):2-14. doi: 10.1053/j.sempedsurg.2011.10.009. Semin Pediatr Surg. 2012. PMID: 22248965 Free PMC article. Review.
Increasing evidence indicates that the biological and molecular features of neuroblastoma significantly influence and are highly predictive of clinical behavior. Because of this, neuroblastoma has served as a paradigm for biological risk assessment and treatm …
Increasing evidence indicates that the biological and molecular features of neuroblastoma significantly influence and are highly pred …
Embryonal brain tumors.
McGovern SL, Grosshans D, Mahajan A. McGovern SL, et al. Cancer J. 2014 Nov-Dec;20(6):397-402. doi: 10.1097/PPO.0000000000000081. Cancer J. 2014. PMID: 25415685 Review.
Embryonal brain tumors are a heterogeneous group of neoplasms that primarily occur in infants and young children. ...It is hoped that the use of proton therapy for these vulnerable patients will translate into decreased long-term neurocognitive, endocrine, va …
Embryonal brain tumors are a heterogeneous group of neoplasms that primarily occur in infants and young children. ...It …
3,750 results